Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
Alexion Pharmaceuticals’ Voydeya (danicopan) became the first medicine to be eligible for a new “early launch premium” introduced under Japan’s FY2024 drug pricing reform. However, the premium was entirely removed due to its low cost disclosure ratio. Voydeya was among…
To read the full story
Related Article
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- BMS’ Reblozyl Now Available in Japan for Anemia in MDS
May 21, 2024
- Pfizer’s PARP Inhibitor Talzenna Now Available in Japan
April 24, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
REGULATORY
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
- MHLW to Reconvene HSC Regulation Panel for First Time in a Year
July 17, 2026
- MHLW Allows Exceptional Concerta Pharmacy Transfers
July 17, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…